

SUPPORTING INFORMATION

Gold(I)-Catalyzed Asymmetric [3+2]-Cycloadditions of -1-Ethoxyethoxy-propiolates and Aldehydes

Feng Liu, Yidong Wang, Weimin Ye, and Junliang Zhang.

Shanghai Key Laboratory of Green Chemistry and Chemical Processes, Department of Chemistry, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China.

Fax:(+86)-021-6223-5039; e-mail : jlzhang@chem.ecnu.edu.cn


General Methods:	S2
Figure S1. X-ray of 3fk	S2
Figure S2. X-ray of (R,R,R)-5bAuCl	S3
Table S1. Additional reaction conditions not included in maintext	S4
General Procedure for asymmetric gold-catalyzed cycloaddition	S4
Characterization Data for New Compounds:	S5
^1H and ^{13}C NMR Spectra of New Compounds (3aa to 3ja)	S22
NOESY of 3ja and 3ka	S72-73

General Methods:

All reactions were carried out in oven-dried standard Schlenk techniques with magnetic stirring. Dichloromethane (DCM) and dichloroethane (DCE) was distilled from CaH₂ under an atmosphere of argon. Toluene was as distilled from Sodium under an atmosphere of argon. ¹H NMR spectra were recorded on a BRUKER 400 (400 MHz) spectrometer. Chemical shifts are reported in ppm from tetramethylsilane(TMS: 0 ppm) with the solvent resonance as the internal standard. Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), and coupling constants (Hz). ¹³C NMR spectra were recorded on a BRUKER 400 (100 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl₃: 77.0 ppm, acetone-*d*₆: 205.87)

Aldehydes were purchased from commercial company and **2a-2f** were synthesized according to the literature procedure¹¹.

Figure S1. X-ray of 3fk



(1) Zhang, G.; Zhang, L. *J. Am. Chem. Soc.* **2008**, *130*, 12598.

Figure S2. X-ray of (*R,R,R*)-5bAuCl





Table S1. Additionally Screened Reaction Conditions^a:



Entry	Ligand(5% mol)	AgNTf ₂ (mol%)	Yield (%)	Ee %
1	(R)-MeO-BIPHEP	10	61	14.1
2	(S)-SEGPHOS	10	49	13.1
3	(R)-MeO-XylBIPHEP	10	65	47
4	(R)-MeO-XylBIPHEP	AgOTf (10)	16	48
5	(R)-MeO-XylBIPHEP	AgSbF ₆ (10)	45	46
6	(R)-MeO-DTF-BIPHEP	10	52	39
7	(R)-MeO-TF-BIPHEP	10	53	42
8	(R)-MeO-DTBM-BIPHEP	10	31	65
9	(S)-MOP	10	50	40
10	(S)-Bn-MOP	10	53	34
11	(R)-DTBM-SEGPHOS	10	20	31
12	(S, R, R)- 4a	5	48	68
13	(R)-MeO-DTF-O-BIPHEP	10	56	45
14 ^b	(S,R,R)- 5a	AgOTf	39	81
15 ^b	(S,R,R)- 5a	AgSbF ₆	50	88
16 ^b	(S,R,R)- 5a	AgOC ₄ F ₇	--	--
17 ^b	(S,R,R)- 5a	AgBF ₄	46	88
18 ^b	(S,R,R)- 5a	AgBAr ₄ ^c	17	91

^a General conditions: substrate **1a** (0.4 mmol, 1 equiv), anisaldehyde **2a** (2 equiv) and LAu_n(NTf₂)_n, (5*n mol% AgNTf₂, n= 1 or 2) in 8 mL solvent at 25 °C for 1h. Isolated yields are shown, unless otherwise noted. ^b Reaction performed at 0 °C. ^c Ar = 3,5-CF₃C₆H₃.

General Procedure for asymmetric gold-catalyzed cycloaddition

After the solution of ligand (5.0 mol %) and Me₂SAuCl (5 mol %) in CH₂Cl₂ was stirred at rt for 2 h, the solvent was removed in vacuum. Then a solution of AgNTf₂ (5 mol %) in DCM (1 mL) was added to the residue and the mixture was stirred at 0 °C for 15 min. The above catalyst solution then was added to the solution of alkyne **1** (0.4 mmol) and aldehyde **2** (0.8 mmol) with 150 mg 3Å MS in DCM (7 mL) at 0 °C. The reaction was determined by TLC, after the less component was consumed, the solution was removed under reduced pressure. The diastereomeric ratio was determined by crude ¹H NMR, the resulting crude mixture was purified by flash column chromatography on silica gel to afford product. The enantiomeric excesses of the products were determined by chiral stationary phase HPLC using a Chiralpak IC, AD-H, AD-3 and Chiralcel OZ-3.


General Procedure A: (*S,R,R*)-**5a** used as the ligand.

General Procedure B: (*R,R,R*)-**5b** used as the ligand.

General Procedure C :(*R*)-MeO-DTBM-BIPHEP as the ligand, Me₂SAuCl (10 mol %).


General Procedure D :(*S*)-MeO-DTBM-BIPHEP as the ligand, Me₂SAuCl (10 mol %).

Characterization Data for New Compounds:




1. (*S*)-isopropyl 4-ethoxy-2-(4-methoxyphenyl)-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.

Prepared according to the general procedure A: 73% yield; 93% ee; white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (d, *J* = 8.4 Hz, 2H), 6.83 (d, *J* = 8.4 Hz, 2H), 5.74(s, 1H), 4.81 -4.73 (m, 1H), 4.68-4.59 (m, 1H), 4.25-4.16 (m, 1H), 3.77 (s, 3H), 1.75-1.57 (m, 9H), 1.32 (t, *J* = 7.2 Hz, 3H), 1.29-1.20 (m, 1H), 1.11 (d, *J* = 6.4 Hz, 3H), 0.76 (d, *J* = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.47, 163.30, 159.29, 134.63, 129.19, 113.30, 102.76, 85.71, 83.59, 69.65, 67.20, 55.19, 34.86, 33.48, 24.99, 21.88, 21.70, 21.45, 21.01, 15.19; MS (EI): m/z (%): 374 (M⁺, 36.12); 285 (100), HRMS calcd for C₂₂H₃₀O₅: 374.2093, found: 374.2094. Enantiomeric excess was determined by HPLC with a Chiraldak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 5.01 min, minor enantiomer tr = 5.99 min.





#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	5.01	462.394	50.14	1	5.01	321.807	96.48
2	5.98	459.745	49.86	2	5.99	11.724	3.52




2. (*S*)-isopropyl 2-(4-(dimethylamino)phenyl)-4-ethoxy-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.

Prepared according to the general procedure A: 65% yield; 97% ee; white solid. **¹H NMR** (400 MHz, CDCl₃) δ 7.22 (d, *J* = 8.0 Hz, 2H), 6.67 (d, *J* = 8.0 Hz, 2H), 5.71 (s, 1H), 4.81-4.74 (m, 1H), 4.66-4.58 (m, 1H), 4.23-4.14 (m, 1H), 2.90 (s, 6H), 1.75-1.58 (m, 9H), 1.32 (t, *J* = 7.2 Hz, 3H), 1.26-1.17 (m, 1H), 1.11 (d, *J* = 6.4 Hz, 3H), 0.79 (d, *J* = 6.0 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 167.19, 163.58, 150.56, 130.52, 128.82, 112.33, 103.09, 85.46, 83.83, 69.54, 67.17, 40.76, 34.94, 33.58, 25.09, 21.95, 21.77, 21.52, 21.10, 15.23; **MS** (EI): m/z (%): 387 (M⁺, 63.19); 148 (100), **HRMS** calcd for C₂₃H₃₃NO₄: 387.2410, found: 387.2412. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 5.11 min, minor enantiomer tr = 6.57 min.




3. (*S,E*)-isopropyl 4-ethoxy-2-styryl-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.

Prepared according to the general procedure A: 73% yield; 88% ee; colorless oil. **¹H NMR** (400 MHz, CDCl₃) δ 7.36 (d, *J* = 7.6 Hz, 2H), 7.31-7.23 (m, 2H), 7.21 (t, *J* = 7.2 Hz, 1H), 6.62 (d, *J* = 15.6 Hz, 1H), 6.18 (dd, *J* = 15.6 Hz, 7.2 Hz, 1H), 5.43 (d, *J* = 7.2 Hz, 1H), 5.10-4.95 (m, 1H), 4.60-4.48 (m, 1H), 4.40-4.29 (m, 1H), 1.70-1.59 (m, 10H), 1.31 (t, *J* = 7.2 Hz, 3H), 2.24 (d, *J* = 6.0 Hz, 3H), 1.15 (d, *J* = 6.4 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 167.78, 163.12, 136.98, 131.45, 130.86, 128.42, 127.43, 126.57, 101.28, 86.22, 82.86, 70.08, 67.45, 35.30, 34.19, 25.00, 21.95, 21.80, 21.72, 21.66, 15.31; **MS** (EI): m/z (%): 370 (M⁺, 4.40); 128 (100), **HRMS** calcd for C₂₃H₃₀O₄: 370.2144, found: 370.2142. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 5.25 min, minor enantiomer tr = 6.30 min.




序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU·min	相对峰面积 %	样品量	类型
1	5.27	n.a.	2127.484	604.919	50.82	n.a.	BMB
2	6.33	n.a.	2221.742	585.406	49.18	n.a.	BMB
总和:			4349.226	1190.325	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	5.27	604.919	50.82	1	5.25	650.177	93.90
2	6.33	585.325	49.18	2	6.30	42.266	6.10




4. (*S*)-isopropyl 4-ethoxy-2-(2-methoxyphenyl)-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.

Prepared according to the general procedure A: 71% yield; 77% ee; colorless oil. **1H NMR** (400 MHz, CDCl₃) δ 7.30-7.26 (m, 1H), 7.23-7.18 (m, 1H), 6.91 (t, J = 7.6 Hz, 1H), 6.83 (d, J = 7.6 Hz, 1H), 6.35 (s, 1H), 4.80-4.60 (m, 2H), 4.28-4.19 (s, 1H), 3.84 (s, 3H), 1.80-1.55 (m, 10H), 1.33 (t, J = 7.2 Hz, 3H), 1.07 (d, J = 6.4 Hz, 3H), 0.64 (d, J = 6.0 Hz, 3H); **13C NMR** (100 MHz, CDCl₃) δ 167.90, 163.23, 157.57, 128.77, 128.73, 120.56, 110.45, 102.64, 96.40, 85.65, 75.99, 69.73, 66.93, 55.37, 34.70, 33.43 25.04, 25.01, 21.91, 21.59, 21.43, 20.71; **MS** (EI): m/z (%): 374 (M⁺, 33.22); 285 (100), **HRMS** calcd for C₂₂H₃₀O₅: 374.2093, found: 374.2094. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (98:2 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 4.85 min, minor enantiomer tr = 7.03 min.




序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU·min	相对峰面积 %	样品量	类型
1	5.01	n.a.	1443.702	466.764	50.02	n.a.	MB*
2	7.35	n.a.	1093.314	466.454	49.98	n.a.	BMB*
总和:			2537.016	933.219	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	5.01	466.764	50.02	1	4.85	611.826	88.45
2	7.35	466.016	49.98	2	7.03	79.895	11.55



5. (S)-isopropyl 2-(2,4-dimethoxyphenyl)-4-ethoxy-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.


Prepared according to the general procedure A: 78% yield; 84% ee; white solid. **¹H NMR** (400 MHz, CDCl₃) δ 7.21 (d, *J* = 8.4 Hz, 1H), 6.45 (d, *J* = 8.4 Hz, 1H), 6.40 (s, 1H), 6.25 (s, 1H), 4.79-4.72 (m, 1H), 4.68-4.60 (m, 1H), 4.25-4.17 (m, 1H), 3.81 (s, 3H), 3.78 (s, 3H), 1.74-1.57 (m, 9H), 1.32 (t, *J* = 6.4 Hz, 3H), 1.60-1.90 (m, 1H), 1.09 (d, *J* = 5.6 Hz, 3H), 0.71 (d, *J* = 5.6 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 167.53, 163.36, 160.33, 158.55, 129.50, 123.40, 104.44, 102.70, 98.01, 85.34, 75.85, 69.58, 66.90, 55.28, 55.24, 34.72, 33.38, 25.02, 21.89, 21.61, 21.42, 20.86, 15.19; **MS (EI)**: m/z (%): 404 (M⁺, 14.87; 165 (100), **HRMS** calcd for C₂₃H₃₂O₆: 404.2199, found: 404.2200. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (98:2 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 7.57 min, minor enantiomer tr = 9.64 min.



序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² /min	相对峰面积 %	样品量	类型
1	7.58	n.a.	658.031	682.750	49.76	n.a.	BM ⁺
2	9.62	n.a.	670.782	689.300	50.24	n.a.	bMB ⁻
总和:			1328.813	1372.050	100.00	0.000	


序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² /min	相对峰面积 %	样品量	类型
1	7.57	n.a.	1273.759	1485.704	92.02	n.a.	BM ⁺
2	9.64	n.a.	113.257	128.760	7.98	n.a.	bMB ⁻
总和:			1387.016	1614.464	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	7.58	82.750	49.76	1	7.57	1485.704	92.02
2	9.62	689.300	50.24	2	9.64	128.760	7.98



6. (R)-isopropyl 4-ethoxy-2-(1H-pyrrol-2-yl)-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.


Prepared according to the general procedure A: 71% yield; 82% ee; white solid. **¹H NMR** (400 MHz, CDCl₃) δ 8.34 (brs, 1H), 6.70-6.68 (m, 1H), 6.15-6.13 (m, 1H), 6.11-6.08 (m, 1H), 5.88 (s, 1H), 4.95-4.87 (m, 1H), 4.57-4.49 (m, 1H), 4.31-4.22 (m, 1H), 1.69-1.59 (m, 10H), 1.31 (t, *J* = 7.2 Hz, 3H), 1.18 (d, *J* = 6.0 Hz, 3H), 0.99 (d, *J* = 6.4 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 167.75, 163.54, 132.87, 117.27, 108.12, 106.89, 101.45, 85.79, 77.44, 70.06, 67.72, 34.97, 33.70, 25.00, 21.80, 21.63, 21.28, 15.29; **MS (EI)**: m/z (%): 333 (M⁺, 54.27); 244 (100), **HRMS** calcd for C₁₉H₂₇NO₄: 333.1940, found: 333.1938. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); minor enantiomer tr = 10.39 min, major enantiomer tr = 12.61 min.



序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² /min	相对峰面积 %	样品量	类型
1	10.12	n.a.	104.835	57.915	49.93	n.a.	BMB
2	12.14	n.a.	107.390	58.085	50.07	n.a.	BMB
总和:			212.225	116.000	100.00	0.000	


序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² /min	相对峰面积 %	样品量	类型
1	10.39	n.a.	201.909	80.923	9.24	n.a.	BMB
2	12.61	n.a.	1914.442	794.523	90.76	n.a.	BMB
总和:			2116.351	875.446	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	10.12	57.915	49.93	1	10.39	80.923	9.24
2	12.14	58.085	50.07	2	12.61	794.446	90.76



7. (*R*)-isopropyl 2-(1-benzyl-1H-indol-3-yl)-4-ethoxy-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.


Prepared according to the general procedure B: 62% yield; 92% ee; white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 7.6 Hz, 1H), 7.28-7.19 (m, 4H), 7.14-7.05 (m, 5H), 6.13 (s, 1H), 5.23 (s, 2H), 4.75-4.64 (m, 2H), 4.22-4.17 (m, 1H), 1.84-1.51 (m, 9H), 1.34 (t, *J* = 7.2 Hz, 3H), 1.22-1.18 (m, 1H), 0.99 (d, *J* = 6.4 Hz, 3H), 0.53 (d, *J* = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.00, 163.77, 137.42, 136.89, 128.59, 127.63, 127.50, 127.28, 126.90, 121.57, 120.32, 119.21, 116.72, 109.46, 102.54, 85.25, 76.79, 69.51, 67.01, 49.96, 34.25, 33.19, 25.05, 21.97, 21.57, 20.85, 15.26; MS (EI): m/z (%): 473 (M⁺, 27.93); 91 (100), HRMS calcd for C₃₀H₃₅NO₄: 473.2566, found: 473.2568. Enantiomeric excess was determined by HPLC with a Chiraldak IC column (98:2 hexane: 2-propanol, 0.8 mL/min, 254 nm); minor enantiomer tr = 6.91 min, major enantiomer tr = 12.10 min.



序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² /min	相对峰面积 %	样品量	类型
1	7.31	n.a.	230.234	63.927	50.33	n.a.	BMB*
2	12.16	n.a.	144.547	63.086	49.67	n.a.	BMB*
总和:			374.781	127.013	100.00	0.000	



序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² /min	相对峰面积 %	样品量	类型
1	6.91	n.a.	17.190	11.685	3.85	n.a.	BMB*
2	12.10	n.a.	286.610	291.995	96.15	n.a.	BMB*
总和:			303.800	303.680	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	7.31	63.927	50.33	1	6.91	11.685	3.85
2	12.16	63.0086	49.67	2	12.10	291.995	96.15



8. (*R*)-isopropyl 2-(1-allyl-1*H*-indol-3-yl)-4-ethoxy-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.



Prepared according to the general procedure B: 70% yield; 87% ee; white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.77 (d, $J = 8.0$ Hz, 1H), 7.26-7.22 (m, 1H), 7.17-7.12 (m, 1H), 7.08-7.04 (m, 2H), 6.13 (s, 1H), 5.98-5.89 (m, 1H), 5.16 (dd, $J = 10.4, 1.2$ Hz, 1H), 5.10 (dd, $J = 16.8, 1.2$ Hz, 1H), 4.76-4.63 (m, 4H), 4.23-4.16 (m, 1H), 1.84-1.52 (m, 9H), 1.34 (t, $J = 7.2$ Hz, 3H), 1.26-1.17 (m, 1H), 1.01 (d, $J = 6.4$ Hz, 3H), 0.57 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.87, 163.78, 136.65, 133.40, 127.28, 127.21, 121.34, 120.24, 119.07, 117.22, 116.30, 109.33, 102.57, 85.20, 76.77, 69.47, 66.96, 48.73, 34.21, 33.10, 25.03, 21.95, 21.57, 21.55, 20.82, 15.23; MS (EI): m/z (%): 423 (M^+ , 100.00); 423 (100), HRMS calcd for $\text{C}_{26}\text{H}_{33}\text{NO}_4$: 423.2410, found: 423.2411. Enantiomeric excess was determined by HPLC with a Chiralcel OZ-3 column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); minor enantiomer tr = 5.46 min, major enantiomer tr = 9.09 min.



9. (*R*)-isopropyl 2-(1-benzyl-5-methoxy-1*H*-indol-3-yl)-4-ethoxy-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.


Prepared according to the general procedure B: 63% yield; 90% ee; white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.27-7.21 (m, 4H), 7.10-7.06 (m, 4H), 6.78 (dd, $J = 8.8, 2.0$ Hz, 1H), 6.11 (s, 1H), 5.19 (s, 2H), 4.77-4.61 (m, 2H), 4.25-4.18 (m, 1H), 3.82 (s, 3H), 1.85-1.54 (m, 9H), 1.34 (t, $J = 7.2$ Hz, 3H), 1.26-1.17 (m, 1H), 1.01 (d, $J = 6.0$ Hz, 3H), 0.57 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.85, 163.71, 153.61, 137.44, 132.08, 128.53, 128.17, 127.63, 127.44, 126.76, 116.06, 111.69, 110.20, 102.39, 102.02, 85.15, 76.76, 69.50, 67.00, 55.66, 50.10,

34.27, 33.11, 25.00, 21.92, 21.58, 21.53, 20.87, 15.24; **MS** (EI): m/z (%): 503 (M^+ , 45.85); 91 (100), **HRMS** calcd for $C_{31}H_{37}NO_5$: 503.2672, found: 503.2670. Enantiomeric excess was determined by HPLC with a Chiralecl OZ-3 column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); minor enantiomer tr = 8.63 min, major enantiomer tr = 13.30 min.




10. (*R*)-isopropyl 4-ethoxy-2-(5-methoxy-1-tosyl-1H-indol-3-yl)-1-oxaspiro[4.5]dec-3-ene-3-carboxylate.

Prepared according to the general procedure **B**: 62% yield; 92% ee; white solid. **¹H NMR** (400 MHz, CDCl₃) δ 7.84 (d, *J* = 9.2 Hz, 1H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.45 (s, 1H), 7.21-7.15 (m, 3H), 6.89 (dd, *J* = 9.2, 2.4 Hz, 1H), 5.99 (s, 1H), 4.75-4.63 (m, 2H), 4.33-4.28 (m, 1H), 3.80 (s, 3H), 2.33 (s, 3H), 1.74-1.44 (m, 9H), 1.35 (t, *J* = 7.2 Hz, 3H), 1.21-1.17 (m, 1H), 1.02 (d, *J* = 6.4 Hz, 3H), 0.51 (d, *J* = 6.4 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 168.23, 162.95, 155.99, 144.71, 135.30, 130.68, 129.97, 129.74, 126.77, 125.59, 124.09, 114.24, 113.56, 103.09, 100.97, 86.07, 76.05, 70.12, 67.24, 55.56, 34.23, 33.23, 24.91, 21.81, 21.62, 21.52, 20.83, 15.30; **MS** (EI): m/z (%): 567 (M^+ , 48.82); 91 (100), **HRMS** calcd for $C_{31}H_{37}NO_7S$: 567.2291, found: 567.2294. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 11.41 min, minor enantiomer tr = 14.53 min.




序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU·min	相对峰面积 %	样品量	类型
1	11.53	n.a.	824.586	324.602	50.11	n.a.	BMB
2	14.71	n.a.	848.948	323.181	49.89	n.a.	BMB
总和:			1673.534	647.783	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	11.53	324.602	50.11	1	11.41	1137.756	95.83
2	14.71	323.181	49.89	2	14.53	49.506	4.17




11. (*S*)-isopropyl 4-ethoxy-2-(4-methoxyphenyl)-5,5-dimethyl-2,5-dihydrofuran-3-carboxylate.

Prepared according to the general procedure A: 68% yield; 94% ee; colorless oil. **1H NMR** (400 MHz, CDCl₃) δ 7.27 (d, *J* = 8.8 Hz, 2H), 6.84 (d, *J* = 8.8 Hz, 2H), 5.76 (s, 1H), 4.83-4.72 (m, 1H), 4.71-4.63 (m, 1H), 4.29-4.20 (m, 1H), 3.77 (s, 3H), 1.42 (s, 3H), 1.39 (s, 3H), 1.33 (t, *J* = 7.2 Hz, 3H), 1.10 (d, *J* = 6.4 Hz, 3H), 7.40 (d, *J* = 6.0 Hz, 3H); **13C NMR** (100 MHz, CDCl₃) δ 167.30, 163.14, 159.37, 134.23, 129.00, 113.42, 102.05, 84.56, 83.63, 69.66, 67.24, 55.17, 26.67, 25.63, 21.66, 20.95, 15.12; **MS** (EI): m/z (%): 334 (M⁺, 15.26); 245 (100), **HRMS** calcd for C₁₉H₂₆O₅: 334.1780, found: 334.1777. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column 95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 5.46 min, minor enantiomer tr = 6.17 min.





序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU·min	相对峰面积 %	样品量	类型
1	5.46	n.a.	816.402	330.941	49.45	n.a.	BM
2	6.17	n.a.	864.358	338.316	50.55	n.a.	MB
总和:			1680.761	669.257	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	5.46	330.941	49.45	1	5.46	280.132	97.13
2	6.17	338.316	50.55	2	6.17	8.255	2.86





12. (S)-isopropyl 2-(4-(dimethylamino)phenyl)-4-ethoxy-5,5-dimethyl-2,5-dihydrofuran-3-carboxylate.

Prepared according to the general procedure A: 82% yield; 96% ee; white solid. **¹H NMR** (400 MHz, CDCl₃) δ 7.20 (dd, *J* = 8.8, 1.8 Hz, 2H), 6.67 (d, *J* = 8.8 Hz, 2H), 5.73 (s, 1H), 4.83-4.73 (m, 1H), 4.71-4.62 (m, 1H), 4.27-4.18 (m, 1H), 2.90 (s, 6H), 1.41 (s, 3H), 1.38 (s, 3H), 1.33 (t, *J* = 7.2 Hz, 3H), 1.11 (d, *J* = 6.0 Hz, 3H), 0.76 (d, *J* = 6.0 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 166.93, 163.36, 150.55, 130.02, 128.56, 112.34, 102.29, 84.25, 83.84, 69.49, 67.15, 40.66, 26.72, 25.68, 21.69, 21.00, 15.12; **MS** (EI): m/z (%): 347 (M⁺, 47.04); 258 (100), **HRMS** calcd for C₂₀H₂₉NO₄: 347.2097, found: 347.2094. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 5.47 min, minor enantiomer tr = 6.83 min.



13. (S,E)-isopropyl 4-ethoxy-5,5-dimethyl-2-styryl-2,5-dihydrofuran-3-carboxylate.


Prepared according to the general procedure A: 66% yield; 93% ee; white solid. **¹H NMR** (400 MHz, CDCl₃) δ 7.38-7.35 (m, 2H), 7.32-7.26 (m, 2H), 7.24-7.19 (m, 1H), 6.62 (d, *J* = 16.0 Hz, 1H) 6.19 (dd, *J* = 16.0, 7.6 Hz, 1H), 5.44 (d, *J* = 7.6 Hz, 1H), 5.03-4.90 (m, 1H), 4.60-4.50 (m, 1H), 4.39-4.30 (m, 1H), 1.42 (s, 3H), 1.37 (s, 3H), 1.31 (t, *J* = 7.6 Hz, 3H), 1.24 (d, *J* = 6.4 Hz, 3H), 1.15 (d, *J* = 6.4 Hz, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 167.48, 163.05, 136.90, 131.88, 130.40, 128.45, 127.52, 126.59, 101.01, 85.01, 82.83, 70.05, 67.54, 27.23, 26.19, 21.96, 21.80, 15.27; **MS** (EI): m/z (%): 330 (M⁺, 6.49); 128 (100), **HRMS** calcd for C₂₀H₂₆O₄: 330.1830, found: 330.1831. Enantiomeric excess was determined by HPLC with a Chiralpak OZ-3 column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 4.51 min, minor enantiomer tr = 4.91 min.




3fd

14. (S)-isopropyl 4-ethoxy-2-(2-methoxyphenyl)-5,5-dimethyl-2,5-dihydrofuran-3-carboxylate.



Prepared according to the general procedure A: 65% yield; 83% ee; colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.27-7.19 (m, 2H), 6.91 (t, $J = 7.6$ Hz, 1H), 6.84 (d, $J = 8.4$ Hz, 1H), 6.36 (s, 1H), 4.81-4.65 (m, 2H), 4.35-4.26 (m, 1H), 3.84 (s, 3H), 1.40 (s, 3H), 1.39 (s, 3H), 1.34 (t, $J = 7.2$ Hz, 3H), 1.08 (d, $J = 6.4$ Hz, 3H), 0.65 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.71, 163.12, 157.67, 130.27, 128.95, 128.38, 120.58, 110.55, 101.68, 84.74, 76.50, 69.86, 67.08, 55.47, 26.60, 25.82, 21.66, 20.77, 15.24; MS (EI): m/z (%): 334 (M^+ , 13.32); 245 (100), HRMS calcd for $\text{C}_{19}\text{H}_{26}\text{O}_5$: 334.1780, found: 334.1777. Enantiomeric excess was determined by HPLC with a Chiralpak OZ-3 column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 4.72 min, minor enantiomer tr = 15.89 min.







15. (S)-isopropyl 2-(2,4-dimethoxyphenyl)-4-ethoxy-5,5-dimethyl-2,5-dihydrofuran-3-carboxylate.

Prepared according to the general procedure A: 78% yield; 92% ee; colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.19 (d, $J = 8.4$ Hz, 1H), 6.46-6.40 (m, 2H), 6.27 (s, 1H), 4.81-4.63 (m, 2H), 4.32-4.23 (m, 1H), 3.81 (s, 3H), 3.78 (s, 3H), 1.38 (s, 6H), 1.34 (t, $J = 7.2$ Hz, 3H), 1.10 (d, $J = 6.4$ Hz, 3H), 0.72 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.34, 163.26, 160.51, 158.69, 129.12, 123.03, 104.42, 101.75, 98.18, 84.43, 76.35, 69.72, 67.07, 55.42, 55.31, 26.62, 25.78, 21.68, 20.94, 15.21; MS (EI): m/z (%): 364 (M^+ , 7.22); 165 (100), HRMS calcd for $\text{C}_{20}\text{H}_{28}\text{O}_6$: 364.1886, found: 364.1885. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 6.44 min, minor enantiomer tr = 7.09 min.




16. (R)-isopropyl 4-ethoxy-5,5-dimethyl-2-(1H-pyrrol-2-yl)-2,5-dihydrofuran-3-carboxylate.


Prepared according to the general procedure A: 70% yield; 87% ee; colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 8.39 (s, 1H), 6.69-6.66 (m, 1H), 6.15-6.12 (m, 1H), 6.11-6.07 (m, 1H), 5.89 (s, 1H), 4.93-4.86 (m, 1H), 4.63-4.54 (m, 1H), 4.32-4.24 (m, 1H), 1.39 (s, 3H), 1.37 (s, 3H), 1.32 (t, $J = 7.2$ Hz, 3H), 1.17 (d, $J = 6.4$ Hz, 3H), 0.94 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.44, 163.36, 132.34, 117.41, 108.15, 107.01, 100.73, 84.57, 77.28, 69.92, 67.68, 26.83, 25.75, 21.72, 21.14, 15.16; MS (EI): m/z (%): 293 (M^+ , 21.83); 204 (100), HRMS calcd for $\text{C}_{16}\text{H}_{23}\text{O}_4$: 293.1627, found: 293.1626. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 8.76 min, minor enantiomer tr = 16.83 min.



17. (*R*)-isopropyl 2-(1-benzyl-1*H*-indol-3-yl)-4-ethoxy-5,5-dimethyl-2,5-dihydrofuran-3-carboxylate.


Prepared according to the general procedure B: 84% yield; 88% ee; white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 7.6 Hz, 1H), 7.28-7.19 (m, 4H), 7.16-7.05 (m, 5H), 6.16 (s, 1H), 5.24 (s, 2H), 4.77-4.66 (m, 2H), 4.27-4.18 (m, 1H), 1.44 (s, 3H), 1.42 (s, 3H), 1.35 (t, *J* = 7.2 Hz, 3H), 1.01 (d, *J* = 6.0 Hz, 3H), 0.55 (d, *J* = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.66, 163.62, 137.38, 136.93, 128.60, 127.58, 127.50, 127.11, 126.82, 121.67, 120.04, 119.36, 116.34, 109.52, 101.92, 84.10, 76.83, 69.53, 67.12, 49.94, 26.28, 25.48, 21.58, 20.85, 15.21; MS (EI): m/z (%): 433 (M⁺, 27.23); 91 (100), HRMS calcd for C₂₇H₃₁NO₄: 433.2253, found: 433.2253. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (98:2 hexane: 2-propanol, 0.8 mL/min, 254 nm); minor enantiomer tr = 13.67 min, major enantiomer tr = 16.03 min.






18. (*R*)-isopropyl 4-ethoxy-2-(5-methoxy-1H-indol-3-yl)-5,5-dimethyl-2,5-dihydrofuran-3-carboxylate.

Prepared according to the general procedure B: 82% yield; 95% ee; white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.84 (d, $J = 9.2$ Hz, 1H), 7.73 (d, $J = 8.4$ Hz, 2H), 7.49 (s, 1H), 7.18 (d, $J = 8.0$ Hz, 2H), 7.12 (d, $J = 2.4$ Hz, 1H), 6.90 (dd, $J = 9.2, 2.4$ Hz, 1H), 6.01 (s, 1H), 4.77-4.66 (m, 2H), 4.36-4.27 (m, 1H), 3.79 (s, 3H), 2.32 (s, 3H), 1.40 (s, 6H), 1.36 (t, $J = 7.2$ Hz, 3H), 1.02 (d, $J = 6.4$ Hz, 3H), 0.51 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.66, 162.79, 156.07, 144.74, 135.26, 130.34, 130.01, 129.75, 126.75, 125.68, 123.31, 114.26, 113.67, 102.81, 100.43, 84.84, 76.14, 70.05, 67.32, 55.53, 26.10, 25.42, 21.59, 21.44, 20.80, 15.22; MS (EI): m/z (%): 527 (M^+ , 47.77); 284 (100). HRMS calcd for $\text{C}_{28}\text{H}_{33}\text{NO}_7\text{S}$: 527.1978, found: 527.1979. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 19.83 min, minor enantiomer tr = 25.83 min.



序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² min	相对峰面积 %	样品量	类型	序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU ² min	相对峰面积 %	样品量	类型
1	19.97	n.a.	440.307	343.161	50.18	n.a.	BMB	1	19.83	n.a.	1883.516	1177.645	97.30	n.a.	BMB
2	25.61	n.a.	429.487	340.647	49.82	n.a.	BMB	2	25.83	n.a.	45.487	32.677	2.70	n.a.	BMB
总和:			869.794	683.808	100.00	0.000		总和:			1929.003	1210.322	100.00	0.000	



#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	19.97	343.161	50.18	1	19.83	1177.645	97.30
2	25.61	340.647	49.82	2	25.83	32.677	2.70



19. (*R*)-isopropyl 4-ethoxy-5,5-dimethyl-2-(1-tosyl-1H-indol-3-yl)-2,5-dihydrofuran-3-carboxylate.


Prepared according to the general procedure B: 79% yield; 95% ee; white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, $J = 8.4$ Hz, 1H), 7.76 (d, $J = 7.6$ Hz, 2H), 7.68 (d, $J = 7.6$ Hz, 1H), 7.53 (s, 1H), 7.28 (t, $J = 7.6$ Hz, 1H), 7.23-7.18 (m, 3H), 6.04 (s, 1H), 4.76-4.66 (m, 2H), 4.34-4.25 (m, 1H), 2.33 (s, 3H), 1.40 (s, 3H), 1.38 (s, 3H), 1.36

(t, $J = 7.6$ Hz, 3H), 1.01 (d, $J = 6.0$ Hz, 3H), 0.46 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.60, 162.71, 144.74, 135.24, 135.17, 129.64, 129.26, 126.67, 124.98, 124.42, 123.21, 122.95, 120.40, 113.29, 100.53, 84.73, 76.08, 69.88, 67.14, 53.33, 25.89, 25.26, 21.41, 21.26, 20.59, 15.07; **MS** (EI): m/z (%): 497 (M^+ , 31.87); 91 (100), **HRMS** calcd for $\text{C}_{27}\text{H}_{31}\text{NO}_6\text{S}$: 497.1872, found: 497.1874. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (90:10 hexane: 2-propanol, 0.8 mL/min, 254 nm); minor enantiomer tr = 7.23 min, major enantiomer tr = 9.67 min.




20. (*S*)-isopropyl 4-ethoxy-2-(4-methoxyphenyl)-1-oxaspiro[4.6]undec-3-ene-3-carboxylate.

Prepared according to the general procedure A: 56% yield; 66% ee; white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.27 (d, $J = 8.4$ Hz, 2H), 6.83 (d, $J = 8.4$ Hz, 2H), 5.68 (s, 1H), 4.79-4.72 (m, 1H), 4.68-4.61 (m, 1H), 4.25-4.18 (m, 1H), 3.79 (s, 3H), 2.15-2.10 (m, 1H), 2.09-1.81 (m, 3H), 1.68-1.43 (m, 8H), 1.33 (t, $J = 7.2$ Hz, 3H), 1.10 (d, $J = 6.4$ Hz, 3H), 0.74 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.15, 163.37, 159.33, 134.52, 129.22, 113.37, 101.82, 89.04, 83.38, 69.82, 67.21, 55.25, 39.55, 37.66, 30.46, 30.15, 22.97, 21.73, 21.01, 15.23; **MS** (EI): m/z (%): 388 (M^+ , 51.42); 301 (100), **HRMS** calcd for $\text{C}_{23}\text{H}_{32}\text{O}_5$: 388.2250, found: 388.2249. Enantiomeric excess was determined by HPLC with a Chiralpak AD-3 column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 5.65 min, minor enantiomer tr = 9.16 min.




序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU·min	相对峰面积 %	样品量	类型
1	5.65	n.a.	584.651	195.681	50.22	n.a.	BMB
2	9.03	n.a.	499.678	193.999	49.78	n.a.	BMB
总和:			1084.329	389.680	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	5.05	195.681	50.22	1	5.65	393.990	82.84
2	9.03	193.999	49.78	2	9.16	81.586	17.16




21. (S)-isopropyl 4-ethoxy-2-(4-methoxyphenyl)-1-oxaspiro[4.4]non-3-ene-3-carboxylate.

Prepared according to the general procedure A: 77% yield; 93% ee; white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.26 (d, $J = 8.4$ Hz, 2H), 6.83 (d, $J = 8.4$ Hz, 2H), 5.71 (s, 1H), 4.81-4.74 (m, 1H), 4.70-4.63 (m, 1H), 4.30-4.23 (m, 1H), 3.78 (s, 3H), 2.13-2.08 (m, 1H), 1.87-1.59 (m, 7H), 1.33 (t, $J = 7.2$ Hz, 3H), 1.11 (d, $J = 6.4$ Hz, 3H), 0.76 (d, $J = 6.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.11, 162.97, 159.39, 134.46, 129.06, 113.44, 103.27, 94.80, 84.07, 69.75, 67.27, 55.26, 38.23, 37.50, 25.22, 25.17, 21.75, 21.05, 15.22; MS (EI): m/z (%): 360 (M^+ , 13.82); 135 (100), HRMS calcd for $\text{C}_{21}\text{H}_{28}\text{O}_5$: 360.1937, found: 360.1938. Enantiomeric excess was determined by HPLC with a Chiralpak IC column (98:2 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 6.95 min, minor enantiomer tr = 10.89 min.



序号	保留时间 min	峰名称	峰高 mAU	峰面积 mAU·min	相对峰面积 %	样品量	类型
1	6.92	n.a.	435.692	181.578	49.91	n.a.	BMB
2	10.89	n.a.	390.133	182.220	50.09	n.a.	BMB
总和:			826.024	363.798	100.00	0.000	


#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	6.92	181.578	49.91	1	6.95	166.394	96.49
2	10.89	182.220	50.09	2	10.89	6.055	3.51



3ia


22. (*2S*,5R)-tert-butyl 4-ethoxy-2-(4-methoxyphenyl)-5-methyl-2,5-dihydrofuran-3-carboxylate.**

Prepared according to the general procedure D: 55% yield; 11.4:1 dr; 96% ee; colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.29 (d, $J = 8.4$ Hz, 2H), 6.86 (d, $J = 8.4$ Hz, 2H), 5.71 (d, $J = 3.6$ Hz, 1H), 4.78-4.71 (m, 1H), 4.60-4.51 (m, 1H), 4.23-4.14 (m, 1H), 3.79 (s, 3H), 1.42 (d, $J = 6.4$ Hz, 3H), 1.34 (d, $J = 7.2$ Hz, 3H), 1.16 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.08, 162.78, 159.44, 134.29, 129.08, 113.42, 104.88, 85.79, 80.23, 78.75, 68.75, 55.20, 27.67, 20.31, 15.15; MS (EI): m/z (%): 334 (M^+ , 5.51); 231 (100), HRMS calcd for $\text{C}_{19}\text{H}_{26}\text{O}_5$: 334.1780, found: 334.1782. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (98:2 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 10.13 min, minor enantiomer tr = 12.26 min.



序号	保留时间 min	峰名称	峰高 mAU	峰面积 $\text{mAU} \cdot \text{min}$	相对峰面积 %	样品量	类型	序号	保留时间 min	峰名称	峰高 mAU	峰面积 $\text{mAU} \cdot \text{min}$	相对峰面积 %	样品量	类型
1	10.10	n.a.	43.610	33.077	49.88	n.a.	BMB*	1	10.13	n.a.	859.346	717.005	98.04	n.a.	BMB*
2	12.27	n.a.	48.936	33.238	50.12	n.a.	BMB*	2	12.26	n.a.	18.747	14.301	1.96	n.a.	BMB*
总和:			92.547	66.314	100.00	0.000		总和:			878.093	731.306	100.00	0.000	

#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	10.10	33.077	49.88	1	10.13	717.005	98.04
2	12.27	33.238	50.12	2	12.26	14.301	1.96




3ja

23. (*2S*,5R)-tert-butyl 4-methoxy-2-(4-methoxyphenyl)-5-methyl-2,5-dihydrofuran-3-carboxylate.**

Prepared according to the general procedure D: 52% yield; 11.6:1 dr; 95% ee; colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.31-7.27 (m, 2H), 6.88-6.84 (m, 2H), 5.70 (d, $J = 3.6$ Hz, 1H), 4.79-4.73 (m, 1H), 4.04 (s, 3H), 3.79 (s, 3H), 1.42 (d, $J = 6.4$ Hz, 3H), 1.16 (s, 9H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.99, 162.74, 159.52, 134.13, 129.12, 113.47, 105.01, 85.78, 80.41, 78.45, 60.49, 55.24, 27.68, 20.30; MS (EI): m/z (%): 320 (M^+ , 7.09); 263 (100), HRMS calcd for $\text{C}_{18}\text{H}_{24}\text{O}_5$: 320.1624, found: 320.1626. Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 hexane: 2-propanol, 0.8 mL/min, 254 nm); major enantiomer tr = 6.44 min, minor enantiomer tr = 7.09 min. The reaction under procedure C using R-6 as chiral ligand afford the same product in 54%


yield, 11.5:1 dr with 95% ee.




序号	保留时间 min	峰名称	峰高	峰面积	相对峰面积	样品量	类型	
			mAU	mAU·min	%			
1	7.39	n.a.	224.851	71.358	50.18	n.a.	BM*	
2	8.70	n.a.	223.765	70.859	49.82	n.a.	MB*	
总和:			448.617	142.216	100.00	0.000		


#	Time (min)	Area	Area %	#	Time (min)	Area	Area %
1	7.39	71.358	50.18	1	7.43	59.626	97.38
2	8.70	70.859	49.82	2	8.71	1.605	2.62

1f-10-128-1H







1f-10-97-2H




1f-10-97-2C






1f-13-6-2C



1f-13-6-1





1f-13-6-1C

— 167.90
— 163.23
— 157.57

— 130.70
— 128.77
— 128.73
— 120.56

— 110.45
— 102.64
— 96.40

— 55.37





1f-10-138-2H
7.272
7.219
7.198

6.463
6.442
6.398
6.253

4.782
4.768
4.753
4.738
4.725
4.680
4.662
4.643
4.625
4.607
4.246
4.229
4.210
4.191
4.173
3.809
3.778


1.735
1.721
1.660
1.614
1.579
1.340
1.323
1.308
1.259
1.195
1.098
1.084
0.714
0.700

— 0.001



1f-10-138-2C

— 167.53	— 129.50
— 163.36	— 123.40
— 160.33	
— 158.55	




— 104.44	— 98.01
— 102.70	


— 85.34	
— 77.32	
— 77.00	
— 76.68	
— 75.85	
— 69.58	
— 66.90	

— 55.28	
— 55.24	


— 34.72	
— 33.38	
— 25.02	
— 21.89	
— 21.61	
— 21.42	
— 20.86	
— 15.19	




1f-10-98-3H






1f-10-98-3C
— 167.75
— 163.54




— 132.87
— 117.27
— 108.12
— 106.89
— 101.45
— 85.79
— 77.44
— 77.32
— 77.00
— 76.68
— 70.06
— 67.72
— 34.97
— 33.70
— 25.00
— 21.80
— 21.63
— 21.28
— 15.29





1f-11-51-1H



1f-11-51-1C



1f-11-21-3H



1f-11-21-3C

— 166.87
— 163.78


— 136.65
— 133.40
↙ 127.28
↙ 127.21
↙ 121.34
↙ 120.24
↙ 119.07
↙ 117.22
↙ 116.30
— 109.33

— 102.57


— 85.20
↙ 77.32
↙ 77.00
↙ 76.77
↙ 76.68
— 69.47
— 66.96

— 48.73


↙ 34.21
↙ 33.10
↙ 25.03
↙ 21.95
↙ 21.57
↙ 21.55
↙ 20.82
↙ 15.23




3ah




1f-11-21-21H




1f-11-21-21C




1f-11-84-2H




1f-11-84-2C




1f-10-146-2H




1f-10-146-2C



1f-10-102-1H



1f-10-102-1C



1f-13-21-1H

7.375

7.372

7.354

7.306

7.293

7.221

7.216

7.210

7.198

6.642

6.602

6.218

6.200

6.179

6.160

5.445

5.426

5.024

5.009

4.993

4.978

4.962

4.596

4.578

4.570

4.560

4.552

4.543

4.535

4.517

4.350

4.342

4.332

4.324

4.306

1.582

1.417

1.368

1.331

1.314

1.296



1.246

1.230


1.154

1.138


0.000




1f-13-21-1C



1f-10-99-2H



1f-10-99-2C



10-95-4H

7.267

7.198

7.177

6.456

6.451

6.435

6.430

6.415

6.409

4.806

4.790

4.774

4.759

4.743

4.716

4.698

4.690

4.681

4.637

4.312

4.295

4.287

4.277

4.251

4.234

3.813

3.780

1.379

1.355

1.337

1.319



1.105

1.089


0.723

0.707


0.000




10-95-4C




1f-13-21-5H



1f-13-21-5C



11-28-1H



11-28-1C

— 166.66
— 163.62



— 137.38
— 136.93
— 128.60
— 127.58
— 127.50
— 127.11
— 126.82
— 121.67
— 120.04
— 119.36
— 116.34
— 109.52

— 101.92


— 84.10
— 77.32
— 77.00
— 76.83
— 76.68
— 69.53
— 67.12

— 49.94


— 26.28
— 25.48
— 21.58
— 20.85
— 15.21




1f-11-85-4H




1f-11-85-4C




1f-11-28-2H




1f-11-28-2C




1f-11-79-1H




1f-11-79-1C




1f-10-146-1H




1f-10-146-1C






1f-12-120-1



1f-12-121-1C





1f-12-117-2C

